BC Innovations | Aug 2, 2019
Distillery Therapeutics

Small molecules that prevent stress granule formation in ALS

DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Six compounds identified through cell-based screening could treat ALS by preventing the formation of stress granules, which have been implicated in disease pathogenesis. Small molecules from five...
BC Innovations | Jul 11, 2018
Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
BC Week In Review | Mar 30, 2018
Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...
BC Extra | Mar 7, 2018
Clinical News

GlycoMimetics falls on Phase III AML trial design

GlycoMimetics Inc. (NASDAQ:GLYC) lost $4.07 (18%) to $18.75 on Tuesday after the company unveiled late Monday the design of its Phase III trial for acute myelogenous leukemia candidate GMI-1271. The primary endpoint of the trial,...
BC Week In Review | Dec 15, 2017
Clinical News

GlycoMimetics reports updated Phase I/II AML data for GMI-1271

GlycoMimetics (NASDAQ:GLYC) reported updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia (AML). The company plans to start a Phase III trial in...
BC Extra | Dec 12, 2017
Clinical News

GlycoMimetics gains on updated AML data at ASH

GlycoMimetics jumped $2.13 (15%) to $16.45 on Tuesday after reporting updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia. The company plans to...
BC Innovations | Jun 27, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Estrone-conjugated liposomes could be used to deliver therapies to ESR1 -positive tumors. The liposomes are composed of distearoylglycerophosphoethanolamine (DSPE) conjugated to polyethylene glycol (PEG) and the ESR1 ligand estrone and loaded with a...
BC Week In Review | May 26, 2017
Clinical News

GlycoMimetics reports Phase I/II OS data for SELE-targeting AML candidate

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago next month, GlycoMimetics Inc. (NASDAQ:GLYC) reported Phase I/II data showing that twice-daily GMI-1271 plus mitoxantrone, etoposide and cytarabine (MEC) led...
BioCentury | Mar 25, 2017
Product Development

Pivotal meeting

Cornerstone Pharmaceuticals Inc. was planning a traditional development pathway for CPI-613 in acute myelogenous leukemia and pancreatic cancer, but FDA nudged the company to go from Phase I to pivotal trials for both indications. According...
BC Week In Review | Dec 15, 2016
Clinical News

GMI-1271: Additional Ph I/II data

Data from 33 evaluable patients with relapsed or refractory AML in an open-label, international Phase I/II trial showed that twice-daily GMI-1271 plus mitoxantrone, etoposide and cytarabine (MEC) led to a complete remission rate of 45%....
Items per page:
1 - 10 of 167